Renalytix Plc (LON:RENX – Get Free Report) shot up 11.5% on Friday . The company traded as high as GBX 2.90 and last traded at GBX 2.90. 3,599,768 shares changed hands during mid-day trading, an increase of 292% from the average session volume of 917,177 shares. The stock had previously closed at GBX 2.60.
Renalytix Price Performance
The stock has a market capitalization of £12.67 million, a price-to-earnings ratio of -0.72 and a beta of 1.79. The company has a fifty day simple moving average of GBX 2.04 and a 200 day simple moving average of GBX 3.17. The company has a debt-to-equity ratio of -483.33, a quick ratio of 2.42 and a current ratio of 1.57.
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).
Recommended Stories
- Five stocks we like better than Renalytix
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.
